Untargeted metabolomics for the early detection of preeclampsia: A systematic review of human studies
PLOS One · 30.03.2026 · 21 (3) · e0339292
DOI: 10.1371/journal.pone.0339292 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS One, online erschienen am 30.03.2026. Verfasst von Celia García-Mañas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Physics, Research Centre CIAIMBITAL, University of Almería, Sacramento, Almería, Spain. Hauptthemen laut MEDLINE: Pre-Eclampsia, Metabolomics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Española Contra el Cáncer.
Abstract (Originalsprache)
This systematic review synthesizes current evidence on metabolomics-based biomarkers for the early prediction or diagnosis of preeclampsia and highlights promising candidates with potential clinical application. Following PRISMA guidelines, a comprehensive search was performed in PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov up to September 2024, using predefined terms related to preeclampsia, metabolomics, and pregnancy. Study selection and risk of bias assessment were conducted with CADIMA, applying PICO-based inclusion criteria and predefined quality appraisal standards. Of 112 records identified, 16 were duplicates, 57 were excluded after title and abstract screening, and 31 after full-text review, leaving 12 studies for inclusion. These comprised cohort, case–cohort, case–control, validation, prospective control, and translational designs. Data extraction captured study characteristics, populations, methodologies, biological matrices, and main findings. Considerable heterogeneity was observed across studies, with limited overlap in identified metabolites. Nonetheless, alanine was reported in serum, lactate was observed in both serum and urine, and glutamate and glutamine were detected across serum, plasma, and placental tissue. These metabolites, interconnected through the Cori and glucose–alanine cycles, have been linked to hepatic dysfunction, immune regulation, and excitotoxicity. Overall, metabolomics shows strong potential as a sensitive tool for biomarker discovery in preeclampsia, though further research is required to confirm findings, improve reproducibility, and integrate metabolomic data with clinical parameters to support personalized medicine approaches. Systematic review registration PROSPERO, CRD42024540619.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Physics, Research Centre CIAIMBITAL, University of Almería, Sacramento, Almería, Spain.
- Torrecárdenas University Hospital, Almería, C. Hermandad de Donantes de Sangre, Spain.
ORCID-Profile: Celia García-Mañas, María Dolores Jara Montes, Ignacio Fernández, Ana Maria Fernandez Alonso
Förderung
- Agencia Española Contra el Cáncer
Zitieren
APA
García-Mañas, C., Jara Montes, M. D., Abreu, A. C., Rodríguez Maresca, M. A., Fernández, I., & Fernandez Alonso, A. M. (2026). Untargeted metabolomics for the early detection of preeclampsia: A systematic review of human studies. PLOS One, 21(3), e0339292. https://doi.org/10.1371/journal.pone.0339292
Vancouver
García-Mañas C, Jara Montes MD, Abreu AC, Rodríguez Maresca MA, Fernández I, Fernandez Alonso AM. Untargeted metabolomics for the early detection of preeclampsia: A systematic review of human studies. PLOS One. 2026;21(3):e0339292. doi:10.1371/journal.pone.0339292
BibTeX
@article{GarcaMaas2026,
author = {García-Mañas, Celia and Jara Montes, María Dolores and Abreu, Ana Cristina and Rodríguez Maresca, Manuel A and Fernández, Ignacio and Fernandez Alonso, Ana Maria},
title = {Untargeted metabolomics for the early detection of preeclampsia: A systematic review of human studies},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {3},
pages = {e0339292},
doi = {10.1371/journal.pone.0339292}
}
EUVIMED